title: Topiramate and accommodation: Does topiramate cause accommodative dysfunction?
abstract: OBJECTIVE
  To investigate the accommodation function in topiramate users.
  
  
  METHODS
  Case-control clinical study.
  
  
  METHODS
  The participants included 16 controls and 22 patients using 100 mg/kg topiramate who were diagnosed with migraine according to the International Classification of Headache Disorders, second edition criteria.
  
  
  METHODS
  One-minute dynamic measurements of refraction with accommodation stimuli of 0 D, 2 D, 2.5 D, 3 D, 4 D, and 5 D were obtained using the open field refractometer WAM-5500 in.
  
  
  RESULTS
  In most of the accommodation stimuli ranges (0 D, 2.5 D, 3 D, and 5 D), topiramate users had a significantly higher accommodative lag compared with controls (p = 0.028, p = 0.014, p = 0.011, and p = 0.011, respectively). The most important causes of accommodative lag were found to be accommodation stimulus and inclusion in the topiramate group (p < 0.001, R2= 0.32, 95% CI 0.22-0.37 and 0.42-0.91, respectively). Multivariate linear regression analysis revealed that the 2 most important predictors of accommodative lag were accommodation stimulus and age (p < 0.001, r = 0.51, 95% CI 0.31-0.32 and 0.67-0.69, respectively) CONCLUSIONS: Even after adjustment for age, accommodative lag is greater across several accommodative stimulus levels in patients using topiramate, which may be related to visual symptoms in topiramate users.
authors.affiliation: Marmara University School of Medicine, Department of Ophthalmology, Istanbul, Turkey. Electronic address: erencerman@yahoo.com.
authors.forename: Eren
authors.initials: E
authors.lastname: Çerman
authors.affiliation: Marmara University School of Medicine, Department of Ophthalmology, Istanbul, Turkey.
authors.forename: Semra
authors.initials: S
authors.lastname: Akkaya Turhan
authors.affiliation: Marmara University School of Medicine, Department of Ophthalmology, Istanbul, Turkey.
authors.forename: Muhsin
authors.initials: M
authors.lastname: Eraslan
authors.affiliation: Marmara University School of Medicine, Department of Neurology, Istanbul, Turkey.
authors.forename: Pınar
authors.initials: P
authors.lastname: Kahraman Koytak
authors.affiliation: Marmara University School of Medicine, Department of Neurology, Istanbul, Turkey.
authors.forename: Özden
authors.initials: Ö
authors.lastname: Kilinç
authors.affiliation: Marmara University School of Medicine, Department of Neurology, Istanbul, Turkey.
authors.forename: Tülin
authors.initials: T
authors.lastname: Tanrıdağ
mesh_terms: D000065:Accommodation, Ocular / Q000187:drug effects*; D000328:Adult; D000927:Anticonvulsants / Q000008:administration & dosage / Q000009:adverse effects; D016022:Case-Control Studies; D004305:Dose-Response Relationship, Drug; D005260:Female; D005632:Fructose / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D006801:Humans; D008297:Male; D008881:Migraine Disorders / Q000517:prevention & control; D009216:Myopia / Q000503:physiopathology; D011379:Prognosis; D012029:Refraction, Ocular / Q000187:drug effects; D000077236:Topiramate; D014787:Vision Tests; D014792:Visual Acuity / Q000187:drug effects*
chemical_list: D000927:Anticonvulsants; D000077236:Topiramate; D005632:Fructose